Biomarker-guided clinical development of the first-in-class anti-inflammatory FPR2/ALX agonist ACT-389949.

Stalder, Anna K; Lott, Dominik; Strasser, Daniel S; Cruz, Hans G; Krause, Andreas; Groenen, Peter M A; Dingemanse, Jasper

Stalder, Anna K; Lott, Dominik; Strasser, Daniel S; Cruz, Hans G; Krause, Andreas; Groenen, Peter M A; Dingemanse, Jasper.

Affiliation

Stalder AK; Translational Science, Drug Discovery Biology, Actelion Pharmaceuticals Ltd, 4123, Allschwil, Switzerland.
Lott D; Clinical Pharmacology, Actelion Pharmaceuticals Ltd, 4123, Allschwil, Switzerland.
Strasser DS; Translational Science, Drug Discovery Biology, Actelion Pharmaceuticals Ltd, 4123, Allschwil, Switzerland.
Cruz HG; Clinical Pharmacology, Actelion Pharmaceuticals Ltd, 4123, Allschwil, Switzerland.
Krause A; Clinical Pharmacology, Actelion Pharmaceuticals Ltd, 4123, Allschwil, Switzerland.
Groenen PM; Translational Science, Drug Discovery Biology, Actelion Pharmaceuticals Ltd, 4123, Allschwil, Switzerland.
Dingemanse J; Clinical Pharmacology, Actelion Pharmaceuticals Ltd, 4123, Allschwil, Switzerland.

Br J Clin Pharmacol ; 83(3): 476-486, 2017 03.

Article de En | MEDLINE | ID: mdl-27730665

Sujet(s)
Mots clés

FACS; FPR2/ALX; LPS challenge; biomarker; cytokines; dose finding; first in class; flow cytometry; inflammation; sputum

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Oxazoles / Triazoles / Récepteurs de la lipoxine / Récepteurs aux peptides formylés Type d'étude: Clinical_trials / Prognostic_studies Limites: Adolescent / Adult / Animals / Humans / Male / Middle aged Langue: En Journal: Br J Clin Pharmacol Année: 2017 Type de document: Article Pays d'affiliation: Suisse Pays de publication: Royaume-Uni

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google